<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019383</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065915</org_study_id>
    <secondary_id>NCI-98-C-0022</secondary_id>
    <secondary_id>NCI-T97-0088</secondary_id>
    <nct_id>NCT00019383</nct_id>
    <nct_alias>NCT00001684</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma</brief_title>
  <official_title>Immunization of Patients With Metastatic Melanoma Using Immunodominant Peptides From the Tyrosinase Protein or Tyrosinase Related Protein-1 (TRP1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Giving&#xD;
      the vaccine with interleukin-2 or sargramostim may help kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of peptide vaccine with or without&#xD;
      adjuvant interleukin-2 or sargramostim in treating patients who have recurrent or refractory&#xD;
      metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether patients with refractory metastatic melanoma undergo partial or&#xD;
           complete response to peptides specific to their HLA-antigen, either alone or when&#xD;
           combined with 1 of 3 adjuvants.&#xD;
&#xD;
        -  Evaluate the immunologic response to the peptide alone or when combined with 1 of 3&#xD;
           adjuvants in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified by HLA status (A1 vs A3 vs A24 vs A31).&#xD;
&#xD;
      Patients are assigned to 1 of 4 vaccine groups:&#xD;
&#xD;
        -  Group 1 (HLA-A1 positive): Patients receive tyrosinase:240-251.&#xD;
&#xD;
        -  Group 2 (HLA-A3 positive): Patients receive gp100:17-25. (closed to accrual 5/17/2000)&#xD;
&#xD;
        -  Group 3 (HLA-A24 positive): Patients receive tyrosinase:206-214.&#xD;
&#xD;
        -  Group 4 (HLA-A31 positive): Patients receive tyrosinase related protein-1. Each peptide&#xD;
           vaccine is separately emulsified in Montanide ISA-51 and administered subcutaneously&#xD;
           into the thigh. Patients are treated with peptide vaccine alone or combined with 1 of 3&#xD;
           possible adjuvants (interleukin-2 (IL-2) IV, IL-2 delayed IV, or sargramostim (GM-CSF)&#xD;
           SQ) depending on the time of entry into study and response to treatment.&#xD;
&#xD;
      At least 4 to 6 patients are accrued for the peptide alone cohort before beginning accrual on&#xD;
      the other cohorts. Any patient who experiences unacceptable toxicity due to adjuvant therapy&#xD;
      is taken off study. If a second patient develops unacceptable toxicity, that schedule of&#xD;
      peptide administration is discontinued.&#xD;
&#xD;
      Patients exhibiting stable, minor, mixed, or partial response may receive up to 12 additional&#xD;
      courses.&#xD;
&#xD;
      Patients are followed for 4-6 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 457 patients will be accrued for this study over 3.5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tyrosinase peptide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tyrosinase-related protein-1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven refractory metastatic melanoma&#xD;
&#xD;
               -  Must be HLA-A1, HLA-A3, HLA-A24, or HLA-A31 positive&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance Status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life Expectancy:&#xD;
&#xD;
          -  Greater than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 90,000/mm^3&#xD;
&#xD;
          -  No coagulation disorder&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  AST or ALT less than 2 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin no greater than 1.6 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No major cardiovascular disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No major respiratory disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  No known allergy to Montanide ISA-51&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  No immunodeficiency disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior biologic therapy&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 3 weeks since prior endocrine therapy&#xD;
&#xD;
          -  No concurrent steroid therapy or other endocrine therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Prior or concurrent surgery for melanoma allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Surgery Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2003</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

